{"entity":{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","aka":[],"tldr":"Eryaspase, an enzyme carried inside red blood cells, did not lengthen survival when added to second-line chemotherapy for pancreatic cancer.","summary":"TRYbeCA-1 randomised patients with metastatic pancreatic adenocarcinoma progressing after first-line treatment to eryaspase plus gemcitabine and nab-paclitaxel or irinotecan-based chemotherapy, or chemotherapy alone. The primary endpoint of overall survival was not met when the trial reported in 2021.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03665441","url":"https://clinicaltrials.gov/study/NCT03665441"},{"label":"Hammel et al., Journal of Clinical Oncology 2025: TRYbeCA-1, eryaspase with chemotherapy as second-line treatment","url":"https://doi.org/10.1200/JCO-25-00872"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["eryaspase","gemcitabine-nab-paclitaxel"],"companies":["phaxiam"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-hammel-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03665441","phase":"3","setting":"Second-line metastatic pancreatic adenocarcinoma: eryaspase with chemotherapy versus chemotherapy alone","sponsor":"Erytech Pharma","result":"Primary overall survival endpoint not met.","started":"2018-09-15","startedType":"actual","yearReported":2021,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Eryaspase + chemotherapy","n":255,"value":7.5},{"name":"Chemotherapy alone","n":257,"value":6.7}],"hr":0.92,"ci":[0.76,1.11],"p":"0.374","source":"https://doi.org/10.1200/JCO-25-00872"},{"endpoint":"Progression-free survival","unit":"months","arms":[{"name":"Eryaspase + chemotherapy","value":3.7},{"name":"Chemotherapy alone","value":3.4}],"hr":0.88,"ci":[0.73,1.07],"p":"0.196","source":"https://doi.org/10.1200/JCO-25-00872"},{"endpoint":"Objective response rate","unit":"%","arms":[{"name":"Eryaspase + chemotherapy","value":16.1},{"name":"Chemotherapy alone","value":12.5}],"source":"https://doi.org/10.1200/JCO-25-00872"}]},"route":"/trials/trybeca-1/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"eryaspase","kind":"drug","name":"Eryaspase","route":"/drugs/eryaspase/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}],"company":[{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/"}],"paper":[{"id":"paper-hammel-j-clin-oncol","kind":"paper","name":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma","route":"/key-papers/paper-hammel-j-clin-oncol/"}],"term":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/"}]}}